Pfizer (NYSE:PFE) Stock Falls 1.4% – Time to Sell?

Shares of Pfizer Inc. (NYSE:PFE) dropped 1.4% during mid-day trading on Monday. The company traded as low as $27.12 and last traded at $27.4150. Approximately 32,348,021 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 40,668,301 shares. The stock had previously closed at $27.80.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s board declared a quarterly dividend of $0.43 per share, payable December 7 to shareholders of record November 6. The payment implies an annualized dividend of $1.72 and a yield of roughly 6.3%, which may attract income-focused investors. Pfizer Declares Fourth-Quarter 2026 Dividend
• Neutral Sentiment: Recent valuation commentary presents Pfizer as inexpensive relative to peers and potentially undervalued, but analysts remain divided. Pfizer’s high yield and lower valuation are offset by slower growth and patent-related risks compared with Johnson & Johnson. Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
• Negative Sentiment: Investors are questioning whether the dividend is sustainable after commentary indicated Pfizer paid out approximately 226% of earnings. Although the high yield supports the stock, a payout above earnings raises the possibility of slower dividend growth or pressure to reduce the distribution if earnings remain weak. Is Pfizer a Good or Bad Investment at Today’s Price?
• Negative Sentiment: Vaxcyte’s VAX-31 matched Pfizer’s Prevnar 20 across all 20 shared serotypes in a Phase 3 study. The results helped drive a sharp rally in Vaxcyte shares and raised concerns that Pfizer’s roughly $6.49 billion Prevnar franchise could face future market-share and pricing pressure. Pfizer’s Prevnar Franchise Faces a New Challenger
• Negative Sentiment: Florida’s attorney general sued Pfizer and CEO Albert Bourla, alleging misleading claims about COVID-19 vaccine safety and undisclosed risks. The allegations could create legal costs, reputational damage and additional regulatory scrutiny, although the claims have not been proven. Florida Attorney General Sues Pfizer

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Bank of America cut their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. lowered their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. HSBC lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. BMO Capital Markets reduced their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.56.

Pfizer Stock Performance

The company has a 50-day simple moving average of $27.50 and a two-hundred day simple moving average of $26.48. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm has a market capitalization of $156.63 billion, a P/E ratio of 36.16, a PEG ratio of 1.84 and a beta of 0.32.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company earned $0.78 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its holdings in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares during the period. State Street Corp boosted its position in shares of Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Pfizer by 11.1% in the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock worth $1,512,948,000 after purchasing an additional 5,364,929 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Pfizer in the 2nd quarter worth approximately $1,049,602,000. Finally, Dimensional Fund Advisors LP increased its position in Pfizer by 0.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after buying an additional 293,029 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.